Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2952W HIGH $2.40
Volume
283.77 K
Value Traded
101.65 K
Short % Float
2.5%
Days to Cover
2.8
+1.43%Week
-3.9%1 Month
+7.48%3 Month
-22.83%6 Month
-96.89%5 Year
-96.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.21 M
EPS (TTM)
-2.04
P/E Ratio
-
Ent. Value
-9.97 M
Total Shares
23.14 M
Float Shares
17.23 M
Insiders
25.54%
Institutions
22.75%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
TSBX Catalyst Timeline
Dated clinical, regulatory and corporate events for Turnstone Biologics Corp.
Past FDA Catalysts and PDUFA Decisions
How TSBX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | TIDAL-01 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TSBX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TIDAL-01 | metastatic colorectal cancer | Phase 1 | 2024-08-14 | overall response rate: 25%; disease control rate: 50%; current therapies or: 1-6%; median progression free survival: 2.0-5.6 months; complete response remission duration: more than one yearRead More | Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jerel DavisDirector, 10% Owner | BuyOffering | 197,458 2,726,322 held | $12.00 | 07/25/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in TSBX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 % | 1.11 M | 3.10 M |
Ownership Trends
TSBX Short Interest
Shares sold short, counted twice a month.
2.5%
Short % of Float
of tradable shares sold short
258.7K
Shares Sold Short
-8.1% vs prior count
2.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
91.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TSBX ranks across every disease it competes in
Competitive Position is a premium feature
See how TSBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTSBX News
About Turnstone Biologics Corp.
BIOPHARMAWATCH ELITE PLUS
Trade the next TSBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime